| CAS ID: | 1190307-88-0 |
| Molecular Formula: | C22H29FN3O9P |
| Molecular Weight: | 529.5 g/mol |
| Monoisotopic Mass: | 529.1625 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | PSI-7977, GS-7977 | SOFOSBUVIR | SOVALDI |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1 | See All |
| InChI Key: | TTZHDVOVKQGIBA-IQWMDFIBSA-N | |
| Smiles: | CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)Oc3ccccc3 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT02319031 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | December 18, 2014 | Last Verified | January 27, 2017 |
| Sponsor | Bristol-Myers Squibb | ||
Trial Record 2
| ClinicalTrial ID | NCT02206932 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Withdrawn |
| First Received | August 1, 2014 | Last Verified | November 25, 2014 |
| Sponsor | University of California, San Francisco | ||
Trial Record 3
| ClinicalTrial ID | NCT02464631 | Disease | Liver fibrosis |
| Phase | Not Applicable | Status | Terminated |
| First Received | June 8, 2015 | Last Verified | January 19, 2017 |
| Sponsor | Institute of Liver and Biliary Sciences, India | ||
Trial Record 4
| ClinicalTrial ID | NCT02705534 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 10, 2016 | Last Verified | April 30, 2018 |
| Sponsor | Tehran University of Medical Sciences | ||
Trial Record 5
| ClinicalTrial ID | NCT02596880 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | November 4, 2015 | Last Verified | October 18, 2016 |
| Sponsor | Tehran University of Medical Sciences | ||
Trial Record 6
| ClinicalTrial ID | NCT01687257 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | September 18, 2012 | Last Verified | September 16, 2016 |
| Sponsor | Gilead Sciences | ||
Trial Record 7
| ClinicalTrial ID | NCT02597166 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | November 5, 2015 | Last Verified | October 25, 2018 |
| Sponsor | University Health Network, Toronto | ||
Trial Record 8
| ClinicalTrial ID | NCT02996682 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | December 19, 2016 | Last Verified | February 26, 2019 |
| Sponsor | Gilead Sciences | ||
Trial Record 9
| ClinicalTrial ID | NCT02201901 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | July 28, 2014 | Last Verified | November 15, 2018 |
| Sponsor | Gilead Sciences | ||
Trial Record 10
| ClinicalTrial ID | NCT02114177 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | April 15, 2014 | Last Verified | April 12, 2016 |
| Sponsor | Janssen Infectious Diseases BVBA | ||
Trial Record 11
| ClinicalTrial ID | NCT02114151 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | April 15, 2014 | Last Verified | April 4, 2016 |
| Sponsor | Janssen Infectious Diseases BVBA | ||
Trial Record 12
| ClinicalTrial ID | NCT02292706 | Disease | Liver fibrosis |
| Phase | Status | Enrolling by invitation | |
| First Received | November 17, 2014 | Last Verified | February 8, 2019 |
| Sponsor | Gilead Sciences | ||
Trial Record 13
| ClinicalTrial ID | NCT02349048 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | January 28, 2015 | Last Verified | March 1, 2017 |
| Sponsor | Janssen Research & Development, LLC | ||
| PubChem: | 45375808 |
| ChEMBL: | CHEMBL1259059 |